Skip to main content
. 2018 Mar;21(3):277–283. doi: 10.22038/ijbms.2018.25382.6275

Figure 1.

Figure 1

Up-regulation of miR-9-5p and down-regulation of miR-106a-5p in CD4+ T-cells of RR-MS patients

(A) The results of RT-qPCR showed higher miR-9-5p expression in relapsing phase of relapsing-remitting MS (RR-MS) (n=20) compared to remitting phase (n=20) and control (n=11) groups. (B) MiR-106a-5p was down-regulated in CD4+ cells of relapsing phase (n=20) and remitting phase (n=20) compared to healthy group (n=11). Bars represents the mean ± SD. ** P<0.01 and ***P <0.001.